Tower Semiconductor Limited Ord (NASDAQ:TSEM) had an increase of 0.04% in short interest. TSEM’s SI was 1.33M shares in January as released by FINRA. Its up 0.04% from 1.33M shares previously. With 565,400 avg volume, 2 days are for Tower Semiconductor Limited Ord (NASDAQ:TSEM)’s short sellers to cover TSEM’s short positions. The SI to Tower Semiconductor Limited Ord’s float is 1.63%. The stock increased 0.55% or $0.19 during the last trading session, reaching $34.97. About 252,815 shares traded. Tower Semiconductor Ltd. (NASDAQ:TSEM) has risen 122.17% since January 13, 2017 and is uptrending. It has outperformed by 105.47% the S&P500.
As announced in a legally required form which was filled with the DC-based SEC on January 12, 2018, David Stack an insider in Pacira Pharmaceuticals Inc and currently CEO and Chairman, made a sale of shares worth $1,160,975 USD in the company. He sold 28,885 shares, at average $40.2 per share. David Stack currently has rights to 0.25% of the market cap of Pacira Pharmaceuticals Inc.
Among 7 analysts covering TowerJazz (NASDAQ:TSEM), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. TowerJazz had 18 analyst reports since August 6, 2015 according to SRatingsIntel. Drexel Hamilton maintained the stock with “Buy” rating in Monday, August 21 report. The firm has “Buy” rating given on Wednesday, November 8 by Craig Hallum. The stock of Tower Semiconductor Ltd. (NASDAQ:TSEM) has “Buy” rating given on Wednesday, November 29 by Drexel Hamilton. The firm earned “Buy” rating on Thursday, August 3 by Drexel Hamilton. The firm has “Buy” rating given on Thursday, September 7 by Needham. On Friday, January 22 the stock rating was initiated by Needham with “Strong Buy”. The firm has “Buy” rating by Drexel Hamilton given on Tuesday, November 7. The stock of Tower Semiconductor Ltd. (NASDAQ:TSEM) earned “Buy” rating by Needham on Thursday, August 3. On Thursday, August 6 the stock rating was maintained by Chardan Capital Markets with “Buy”. The firm earned “Buy” rating on Monday, August 21 by Needham.
Tower Semiconductor Ltd., an independent semiconductor foundry, makes and markets analog intensive mixed-signal semiconductor devices in the United States, Asia, and Europe. The company has market cap of $3.43 billion. The firm provides various customizable process technologies, including silicon-germanium, BiCMOS, mixed-signal/complementary metal oxide semiconductor , radio frequency CMOS, CMOS image sensor, integrated power management, and micro-electro-mechanical systems. It has a 17.72 P/E ratio. It also offers transfer optimization and development process services to integrated device manufacturers and fabless companies.
Since August 15, 2017, it had 0 buys, and 4 insider sales for $1.23 million activity. The insider HASTINGS PAUL J sold 1,044 shares worth $37,741. 340 shares valued at $14,858 were sold by Riker Lauren Bullaro on Friday, December 15. $1.05M worth of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) shares were sold by STACK DAVID M. Williams Kristen Marie had sold 3,461 shares worth $127,192.
Investors sentiment decreased to 1.39 in Q3 2017. Its down 0.23, from 1.62 in 2017Q2. It fall, as 35 investors sold Pacira Pharmaceuticals, Inc. shares while 37 reduced holdings. 29 funds opened positions while 71 raised stakes. 41.63 million shares or 5.80% more from 39.35 million shares in 2017Q2 were reported. Morgan Stanley owns 94,034 shares or 0% of their US portfolio. Rhumbline Advisers holds 0% or 50,179 shares in its portfolio. Avenir stated it has 12,120 shares or 0.04% of all its holdings. Alyeska Inv Gp Limited Partnership owns 638,943 shares. Oak Ridge Invests Limited Liability has invested 0.55% in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Sei Invests holds 0% or 25,539 shares in its portfolio. Great Lakes Advsrs Ltd accumulated 0.11% or 122,083 shares. Mutual Of America invested in 0.09% or 151,078 shares. Pub Employees Retirement Systems Of Ohio holds 0.01% or 40,174 shares in its portfolio. Moreover, Evercore Wealth Mngmt Ltd Limited Liability Company has 0% invested in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Moreover, Baillie Gifford And has 0.02% invested in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) for 320,582 shares. 40 North Mngmt Lc stated it has 399,496 shares or 3.16% of all its holdings. Schroder Investment Management Group Inc reported 0.06% stake. Patten Grp Inc accumulated 11 shares or 0% of the stock. Voya Investment Mngmt Ltd Liability holds 0.05% or 590,995 shares.
Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, makes, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. The company has market cap of $1.68 billion. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. It currently has negative earnings. The companyÂ’s lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia.
Analysts await Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) to report earnings on March, 7. They expect $-0.08 EPS, up 33.33% or $0.04 from last year’s $-0.12 per share. After $-0.11 actual EPS reported by Pacira Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -27.27% EPS growth.
Among 21 analysts covering Pacira Pharmaceuticals (NASDAQ:PCRX), 11 have Buy rating, 1 Sell and 9 Hold. Therefore 52% are positive. Pacira Pharmaceuticals has $113 highest and $31 lowest target. $55.67’s average target is 34.14% above currents $41.5 stock price. Pacira Pharmaceuticals had 80 analyst reports since July 28, 2015 according to SRatingsIntel. Mizuho maintained the stock with “Buy” rating in Wednesday, August 2 report. On Wednesday, December 21 the stock rating was maintained by Mizuho with “Buy”. The firm earned “Buy” rating on Monday, September 26 by Jefferies. On Friday, October 7 the stock rating was reinitiated by Brean Capital with “Hold”. The stock of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) has “Buy” rating given on Wednesday, July 19 by Wedbush. The stock of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) has “Buy” rating given on Wednesday, June 21 by Wedbush. JMP Securities reinitiated the stock with “Mkt Outperform” rating in Tuesday, January 5 report. The stock has “Hold” rating by Canaccord Genuity on Wednesday, November 29. The firm has “Buy” rating by Wedbush given on Monday, August 7. BMO Capital Markets maintained it with “Hold” rating and $39.0 target in Wednesday, November 8 report.
The stock decreased 1.72% or $0.72 during the last trading session, reaching $41.5. About 1.03M shares traded or 26.82% up from the average. Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) has risen 12.40% since January 13, 2017 and is uptrending. It has underperformed by 4.30% the S&P500.